Descriptive epidemiology of craniopharyngiomas in the United States

Abstract

Purpose

Craniopharyngiomas are rare benign brain tumors originating from errors in differentiation during embryogenesis. Given current interest in treatments that target genetic and molecular signatures of specific craniopharyngioma subtypes, updated and comprehensive epidemiologic data of these subtypes are necessary to inform and direct resources.

Methods

We utilized data from the Central Brain Tumor Registry of the United States (CBTRUS), which represents 100% of the US population. Incidence by demographics was calculated only for histologically-confirmed cases. Age-adjusted annual incidence was calculated and is reported per 100,000 persons. Annual percent change (APC) in incidence rates from 2004 to 2016 was calculated to assess trends.

Results

From 2004 to 2016, 7441 craniopharyngiomas were diagnosed in the United States, representing approximately 620 new cases each year. The incidence for histologically-confirmed cases was 0.16 per 100,000 persons. The age distribution was bimodal, with one peak in 5- to 9-year-olds and another in 55- to 69-year-olds. Compared with adamantinomatous tumors, papillary craniopharyngiomas only represented 5.5% of the histologically diagnosed craniopharyngiomas in 0- to 29-year-olds, 30.6% in 30- to 59-year-olds, and 30.4% in 60 + year-olds. Incidence was highest amongst Blacks (0.22), followed by Whites (0.15), Asians or Pacific Islanders (0.14), and American Indians/Alaska Natives (0.10). No significant difference was discovered in incidence rates between males and females or Hispanic and non-Hispanic ethnicities.

Conclusions

Craniopharyngiomas are rare tumors with a bimodal age distribution and an equal male-to-female incidence. Black patients had the highest incidence, and adamantinomatous craniopharyngiomas were significantly more common than papillary tumors in adolescent, adult, and elderly populations.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. 1.

    Müller HL, Merchant TE, Warmuth-Metz M et al (2019) Craniopharyngioma. Nat Rev Dis Prim. https://doi.org/10.1038/s41572-019-0125-9

    Article  PubMed  Google Scholar 

  2. 2.

    Ostrom QT, Cioffi G, Gittleman H et al (2019) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016. Neuro Oncol 21:v1–v100. https://doi.org/10.1093/neuonc/noz150

    Article  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Cossu G, Jouanneau E, Cavallo LM et al (2020) Surgical management of craniopharyngiomas in adult patients: a systematic review and consensus statement on behalf of the EANS skull base section. Acta Neurochir (Wien) 162:1159–1177. https://doi.org/10.1007/s00701-020-04265-1

    Article  Google Scholar 

  4. 4.

    Bunin GR, Surawicz TS, Witman PA et al (1998) The descriptive epidemiology of craniopharyngioma. J Neurosurg 89:547–551. https://doi.org/10.3171/jns.1998.89.4.0547

    CAS  Article  PubMed  Google Scholar 

  5. 5.

    Zacharia BE, Bruce SS, Goldstein H et al (2012) Incidence, treatment and survival of patients with craniopharyngioma in the surveillance, epidemiology and end results program. Neuro Oncol 14:1070–1078. https://doi.org/10.1093/neuonc/nos142

    Article  PubMed  PubMed Central  Google Scholar 

  6. 6.

    Gupta S, Bi WL, Giantini Larsen A et al (2018) Craniopharyngioma: a roadmap for scientific translation. Neurosurg Focus 44:E12. https://doi.org/10.3171/2018.3.FOCUS1861

    Article  PubMed  Google Scholar 

  7. 7.

    Aylwin SJB, Bodi I, Beaney R (2015) Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor. Pituitary 19:544–546

    Article  Google Scholar 

  8. 8.

    Brastianos PK, Shankar GM, Gill CM et al (2016) Dramatic response of BRAF V600E mutant papillary craniopharyngioma to targeted therapy. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djv310

    Article  PubMed  Google Scholar 

  9. 9.

    Sorva R, Heiskanen O (1986) Craniopharyngioma in Finland. A study of 123 cases. Acta Neurochir (Wien) 81:85–89. https://doi.org/10.1007/BF01401226

    CAS  Article  Google Scholar 

  10. 10.

    Weiner HL, Wisoff JH, Rosenberg ME et al (1994) Craniopharyngiomas: a clinicopathological analysis of factors predictive of recurrence and functional outcome. Neurosurgery 35:1001. https://doi.org/10.1227/00006123-199412000-00001

    CAS  Article  PubMed  Google Scholar 

  11. 11.

    Crotty TB, Scheithauer BW, Young WFJ et al (1995) Papillary craniopharyngioma: a clinicopathological study of 48 cases. J Neurosurg 83:206–214. https://doi.org/10.3171/jns.1995.83.2.0206

    CAS  Article  PubMed  Google Scholar 

Download references

Funding

Not applicable.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Varun R. Kshettry.

Ethics declarations

Conflict of interest

Pablo F. Recinos (consultant, Stryker); Varun R. Kshettry (consultant, Stryker, Integra).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (JPG 104 KB)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Momin, A.A., Recinos, M.A., Cioffi, G. et al. Descriptive epidemiology of craniopharyngiomas in the United States. Pituitary (2021). https://doi.org/10.1007/s11102-021-01127-6

Download citation

Keywords

  • Craniopharyngiomas
  • Epidemiology
  • Adamantinomatous
  • Papillary
  • CBTRUS